The FDA decision on the expanded use of Lynparza in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer is expected in the fourth quarter of this year.Lynparza is being jointly developed and commercialized by AstraZeneca and Merck and Co. (MRK).In the indication of prostate cancer, the drug is already approved for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with Enzalutamide or Abiraterone.Ovarian cancer, breast cancer, and pancreatic cancer are the other indications for which Lynparza is already approved in the U.S. MRK closed Thursday’s (Sep.29,2022) trading at $86.64, down 0.16%.